source
- Amgen's daxdilimab shows 6-point CLASI-A reduction in phase 2 lupus trialAmgen reported data from its phase 2 study of the ILT7-targeting monoclonal antibody daxdilimab in patients with discoid lupus. The trial enrolled 72 patients and tested two dose levels. The lower…
- Merck reports positive phase 2b results for anti-TL1A antibody in hidradenitis suppurativaMerck announced that its experimental anti-TL1A antibody achieved a positive outcome in a phase 2b study. The trial enrolled patients with moderate to severe hidradenitis suppurativa, a chronic in…